logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Swire Pacific B (00087) spent 1.86 million Hong Kong dollars on repurchasing 187,500 shares on September 20th.

date
18:05 20/09/2024
avatar
GMT Eight
The announcement was made by TAIGU Holdings Company B (00087) on September 20, 2024, stating that the company had invested 186.08...
SWIRE PACIFIC B (00087) announced that the company has repurchased 187,500 shares at a total cost of HK$1.8608 million on September 20, 2024, with a repurchase price ranging from HK$9.76 to HK$9.97 per share.
Related Articles
HK Stock
On March 31st, STANCHART (02888) spent 15.3417 million pounds to repurchase 984,000 shares.
HK Stock
POP MART (09992) spent 99.44596 million Hong Kong dollars on April 1st to repurchase 670,000 shares.
China Stock
Shanghai Fosun Pharmaceutical's subsidiary drug HLX319 has received approval for clinical trials.
On March 31st, STANCHART (02888) spent 15.3417 million pounds to repurchase 984,000 shares.
HK Stock
POP MART (09992) spent 99.44596 million Hong Kong dollars on April 1st to repurchase 670,000 shares.
HK Stock
Shanghai Fosun Pharmaceutical's subsidiary drug HLX319 has received approval for clinical trials.
China Stock
RECOMMEND
The “Google Panic” In Memory Stocks: New Cycle Dynamics Beneath Technological Headlines
The “Google Panic” In Memory Stocks: New Cycle Dynamics Beneath Technological Headlines
icon
01/04/2026
Price Increase Cycle Begins, Semiconductor Industry Enters New Stage Of Rising Volume And Value
Price Increase Cycle Begins, Semiconductor Industry Enters New Stage Of Rising Volume And Value
icon
01/04/2026
When Will Hong Kong Stocks Reach Their Low Point?
When Will Hong Kong Stocks Reach Their Low Point?
icon
01/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.